Narcolepsy - Pipeline Review, H1 2020
Narcolepsy - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H1 2020, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.
Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6, 4, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H1 2020, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.
Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6, 4, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Narcolepsy - Overview
Narcolepsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Narcolepsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Narcolepsy - Companies Involved in Therapeutics Development
Avadel Pharmaceuticals Plc
Axsome Therapeutics Inc
Balance Therapeutics Inc
Bioprojet SCR
F. Hoffmann-La Roche Ltd
Inexia Ltd
Jazz Pharmaceuticals Plc
NLS Pharma Group
Ono Pharmaceutical Co Ltd
Orexia Ltd
Seelos Therapeutics, Inc.
Suven Life Sciences Ltd
Takeda Pharmaceutical Co Ltd
Theranexus SAS
Vallon Pharmaceuticals Inc
XW Laboratories Inc
Narcolepsy - Drug Profiles
(flecainide acetate + modafinil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbaclofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dextroamphetamine IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-258 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLS-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oxybate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentylenetetrazol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pitolisant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reboxetine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLS-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium oxybate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVNG-3031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-994 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XWL-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Narcolepsy - Dormant Projects
Narcolepsy - Discontinued Products
Narcolepsy - Product Development Milestones
Featured News & Press Releases
Mar 30, 2020: Harmony Biosciences highlights publication Of narcolepsy treatment scientific review in sleep medicine
Mar 25, 2020: Avadel Pharmaceuticals completes the REST-ON Phase 3 Pivotal trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
Mar 25, 2020: Jazz Pharmaceuticals announces FDA acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Jan 22, 2020: Jazz Pharmaceuticals submits new drug application for JZP-258 for cataplexy and excessive daytime sleepiness associated with narcolepsy
Dec 17, 2019: Avadel Pharmaceuticals completes enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
Dec 03, 2019: Axsome Therapeutics announces AXS-12 achieves primary endpoint in CONCERT phase 2 trial in Narcolepsy
Dec 02, 2019: Avadel Pharmaceuticals announces key appointments to leadership team to support continued transformation and the advancement of FT218
Nov 25, 2019: Avadel Pharmaceuticals achieves enrollment target in REST-ON phase 3 pivotal trial of FT218 for excessive daytime sleepiness and Cataplexy in patients with Narcolepsy
Nov 20, 2019: Harmony Biosciences announces publication of data in sleep from two clinical studies of WAKIX (pitolisant)
Oct 21, 2019: Axsome Therapeutics completes patient enrollment in the CONCERT Phase 2 trial of AXS-12 in narcolepsy
Oct 02, 2019: Axsome Therapeutics to Provide Update on AXS-12 at the 2019 Cantor Global Healthcare Conference
Sep 26, 2019: New data presented on TAK-994, an oral selective OX2R agonist at World Sleep Congress
Sep 26, 2019: New data presented at World Sleep Congress demonstrate early signs of efficacy for TAK-925,, a selective orexin type-2 receptor (OX2R) agonist, in patients with narcolepsy type 1
Sep 25, 2019: Jazz Pharmaceuticals presents positive JZP-258 phase 3 study data at World Sleep 2019
Sep 24, 2019: First patient randomized in a Phase 2A, Proof of Concept (PoC) clinical trial of SUVN-G3031 for the treatment of Narcolepsy associated with or without Cataplexy in USA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Narcolepsy - Overview
Narcolepsy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Narcolepsy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Narcolepsy - Companies Involved in Therapeutics Development
Avadel Pharmaceuticals Plc
Axsome Therapeutics Inc
Balance Therapeutics Inc
Bioprojet SCR
F. Hoffmann-La Roche Ltd
Inexia Ltd
Jazz Pharmaceuticals Plc
NLS Pharma Group
Ono Pharmaceutical Co Ltd
Orexia Ltd
Seelos Therapeutics, Inc.
Suven Life Sciences Ltd
Takeda Pharmaceutical Co Ltd
Theranexus SAS
Vallon Pharmaceuticals Inc
XW Laboratories Inc
Narcolepsy - Drug Profiles
(flecainide acetate + modafinil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbaclofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dextroamphetamine IR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JZP-258 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mazindol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLS-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONO-4127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oxybate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentylenetetrazol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pitolisant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reboxetine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5256390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLS-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium oxybate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUVNG-3031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-925 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-994 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XWL-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Narcolepsy - Dormant Projects
Narcolepsy - Discontinued Products
Narcolepsy - Product Development Milestones
Featured News & Press Releases
Mar 30, 2020: Harmony Biosciences highlights publication Of narcolepsy treatment scientific review in sleep medicine
Mar 25, 2020: Avadel Pharmaceuticals completes the REST-ON Phase 3 Pivotal trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
Mar 25, 2020: Jazz Pharmaceuticals announces FDA acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
Jan 22, 2020: Jazz Pharmaceuticals submits new drug application for JZP-258 for cataplexy and excessive daytime sleepiness associated with narcolepsy
Dec 17, 2019: Avadel Pharmaceuticals completes enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
Dec 03, 2019: Axsome Therapeutics announces AXS-12 achieves primary endpoint in CONCERT phase 2 trial in Narcolepsy
Dec 02, 2019: Avadel Pharmaceuticals announces key appointments to leadership team to support continued transformation and the advancement of FT218
Nov 25, 2019: Avadel Pharmaceuticals achieves enrollment target in REST-ON phase 3 pivotal trial of FT218 for excessive daytime sleepiness and Cataplexy in patients with Narcolepsy
Nov 20, 2019: Harmony Biosciences announces publication of data in sleep from two clinical studies of WAKIX (pitolisant)
Oct 21, 2019: Axsome Therapeutics completes patient enrollment in the CONCERT Phase 2 trial of AXS-12 in narcolepsy
Oct 02, 2019: Axsome Therapeutics to Provide Update on AXS-12 at the 2019 Cantor Global Healthcare Conference
Sep 26, 2019: New data presented on TAK-994, an oral selective OX2R agonist at World Sleep Congress
Sep 26, 2019: New data presented at World Sleep Congress demonstrate early signs of efficacy for TAK-925,, a selective orexin type-2 receptor (OX2R) agonist, in patients with narcolepsy type 1
Sep 25, 2019: Jazz Pharmaceuticals presents positive JZP-258 phase 3 study data at World Sleep 2019
Sep 24, 2019: First patient randomized in a Phase 2A, Proof of Concept (PoC) clinical trial of SUVN-G3031 for the treatment of Narcolepsy associated with or without Cataplexy in USA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Narcolepsy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Narcolepsy - Pipeline by Avadel Pharmaceuticals Plc, H1 2020
Narcolepsy - Pipeline by Axsome Therapeutics Inc, H1 2020
Narcolepsy - Pipeline by Balance Therapeutics Inc, H1 2020
Narcolepsy - Pipeline by Bioprojet SCR, H1 2020
Narcolepsy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Narcolepsy - Pipeline by Inexia Ltd, H1 2020
Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H1 2020
Narcolepsy - Pipeline by NLS Pharma Group, H1 2020
Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
Narcolepsy - Pipeline by Orexia Ltd, H1 2020
Narcolepsy - Pipeline by Seelos Therapeutics, Inc., H1 2020
Narcolepsy - Pipeline by Suven Life Sciences Ltd, H1 2020
Narcolepsy - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Narcolepsy - Pipeline by Theranexus SAS, H1 2020
Narcolepsy - Pipeline by Vallon Pharmaceuticals Inc, H1 2020
Narcolepsy - Pipeline by XW Laboratories Inc, H1 2020
Narcolepsy - Dormant Projects, H1 2020
Narcolepsy - Dormant Projects, H1 2020 (Contd..1), H1 2020
Narcolepsy - Discontinued Products, H1 2020
Number of Products under Development for Narcolepsy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Narcolepsy - Pipeline by Avadel Pharmaceuticals Plc, H1 2020
Narcolepsy - Pipeline by Axsome Therapeutics Inc, H1 2020
Narcolepsy - Pipeline by Balance Therapeutics Inc, H1 2020
Narcolepsy - Pipeline by Bioprojet SCR, H1 2020
Narcolepsy - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Narcolepsy - Pipeline by Inexia Ltd, H1 2020
Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H1 2020
Narcolepsy - Pipeline by NLS Pharma Group, H1 2020
Narcolepsy - Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
Narcolepsy - Pipeline by Orexia Ltd, H1 2020
Narcolepsy - Pipeline by Seelos Therapeutics, Inc., H1 2020
Narcolepsy - Pipeline by Suven Life Sciences Ltd, H1 2020
Narcolepsy - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Narcolepsy - Pipeline by Theranexus SAS, H1 2020
Narcolepsy - Pipeline by Vallon Pharmaceuticals Inc, H1 2020
Narcolepsy - Pipeline by XW Laboratories Inc, H1 2020
Narcolepsy - Dormant Projects, H1 2020
Narcolepsy - Dormant Projects, H1 2020 (Contd..1), H1 2020
Narcolepsy - Discontinued Products, H1 2020
LIST OF FIGURES
Number of Products under Development for Narcolepsy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Avadel Pharmaceuticals Plc
Axsome Therapeutics Inc
Balance Therapeutics Inc
Bioprojet SCR
F. Hoffmann-La Roche Ltd
Inexia Ltd
Jazz Pharmaceuticals Plc
NLS Pharma Group
Ono Pharmaceutical Co Ltd
Orexia Ltd
Seelos Therapeutics, Inc.
Suven Life Sciences Ltd
Takeda Pharmaceutical Co Ltd
Theranexus SAS
Vallon Pharmaceuticals Inc
XW Laboratories Inc
Number of Products under Development for Narcolepsy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
COMPANIES MENTIONED
Avadel Pharmaceuticals Plc
Axsome Therapeutics Inc
Balance Therapeutics Inc
Bioprojet SCR
F. Hoffmann-La Roche Ltd
Inexia Ltd
Jazz Pharmaceuticals Plc
NLS Pharma Group
Ono Pharmaceutical Co Ltd
Orexia Ltd
Seelos Therapeutics, Inc.
Suven Life Sciences Ltd
Takeda Pharmaceutical Co Ltd
Theranexus SAS
Vallon Pharmaceuticals Inc
XW Laboratories Inc
